Medicines for Malaria (MMV)

The Medicines for Malaria Venture (MMV) is a product development partnership in the field of antimalarial drug research and development.

Its mission is to reduce the burden of malaria by discovering, developing, and delivering new, effective, and affordable antimalarial medicines.

In partnership with MMV, USAID helped advance Coartem Dispersiblethe first child-friendly artemisinin-based combination therapy for malaria, which has since been introduced in over 50 countries. MMV also supported the development of tafenoquine, a single-dose cure for relapsing malaria.

Support from USAID also contributed to the progression of three new classes of antimalarial drugs with the potential to be effective against drug-resistant strains of the parasite.